Analysts Set Expectations for Imunon, Inc.’s Q1 2024 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNNFree Report) – Analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Imunon in a report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.68) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Imunon’s current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Imunon’s Q2 2024 earnings at ($0.69) EPS, Q3 2024 earnings at ($0.71) EPS, Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($2.45) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.61) EPS and FY2027 earnings at ($0.43) EPS.

Imunon Stock Down 20.6 %

IMNN opened at $1.39 on Wednesday. Imunon has a 12-month low of $0.48 and a 12-month high of $2.00. The stock has a market cap of $13.07 million, a price-to-earnings ratio of -0.64 and a beta of 2.03. The business has a 50 day moving average of $0.83 and a 200-day moving average of $0.87.

Hedge Funds Weigh In On Imunon

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC bought a new position in shares of Imunon in the 1st quarter valued at $62,000. Renaissance Technologies LLC bought a new stake in Imunon during the 1st quarter worth $76,000. Finally, BlackRock Inc. bought a new stake in Imunon during the 1st quarter worth $83,000. 4.47% of the stock is owned by institutional investors and hedge funds.

About Imunon

(Get Free Report)

Imunon, Inc, a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.

Further Reading

Earnings History and Estimates for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with's FREE daily email newsletter.